View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
ACR Open Rheumatol. 2023;5(7):345-353 doi 10.1002/acr2.11577
Cicirello, et al. present results showing that baricitinib is comparable in treatment persistence with TNF inhibitors. However, treatment persistence up to 24 months was significantly longer for baricitinib, but the effect size of one month is not clinically meaningful.
Mod Rheumatol 2023;34(3):453–65 doi: 10.1093/mr/road059
Pots hoc analysis of peficitinib Phase 3 trials shows that continued treatment with peficitinib up to Week 52 is linked to improved remission rates in Asian patients with RA.
Int J Rheum Dis. 2023;26(9):1729–1736 doi: 10.1111/1756-185X.14801
This single-centre study by Khan, et al. suggests that high-dose methotrexate (25 mg/week, subcutaneously) may be as efficacious as tofacitinib in patients with established RA who are DMARD naïve or have not received a therapeutic dose of DMARDs.
Inflammopharmacology. 2022. Epub ahead of print doi: 10.1007/s10787-022-00936-w
This study of the effectiveness of JAKinibs or abatacept in patients with RA-interstitial lung disease (RA-ILD) shows that treatment is related to stability or improvement of RA-ILD in over 80% of patients.
Semin Arthritis Rheum. 2022 doi: 10.1016/j.semarthrit.2022.151979
The authors reviewed drug survival of therapies across common inflammatory skin and joint conditions from national registries. The findings highlighted that despite the overlapping pathogenesis of these conditions there was little similarity in drug survival. This reinforces the need for an individualised treatment approach consistent with the underlying disease, patient profile and treatment history.
